Tags

Type your tag names separated by a space and hit enter

Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients.
Scand J Infect Dis. 2008; 40(1):78-80.SJ

Abstract

We carried out a retrospective and descriptive study of 4 HIV infected patients with relapsing visceral leishmaniasis (VL) seen at 2 tertiary-care hospitals in Spain during the last 6 y, in whom miltefosine was used as a compassionate use treatment at a dosage of 50 mg b.i.d. Patients had a medium CD4 lymphocyte count of 69 cells/microl and were C stage. All patients received at least 2 different anti-leishmanial drugs and had at least 3 relapses before miltefosine treatment (range 3-7). Three patients were treated with miltefosine at a standard dose of 50 mg b.i.d. for 28 d, and the other during 12 months. Despite an initial symptomatic improvement, miltefosine treatment failed to eradicate the infection in all cases. We conclude that the use of miltefosine alone is not strong enough to cure relapsing VL in HIV-1 controlled infected patients.

Authors+Show Affiliations

From Infectious Diseases, Madrid, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

17852921

Citation

Troya, Jesús, et al. "Long Term Failure of Miltefosine in the Treatment of Refractory Visceral Leishmaniasis in AIDS Patients." Scandinavian Journal of Infectious Diseases, vol. 40, no. 1, 2008, pp. 78-80.
Troya J, Casquero A, Refoyo E, et al. Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients. Scand J Infect Dis. 2008;40(1):78-80.
Troya, J., Casquero, A., Refoyo, E., Fernández-Guerrero, M. L., & Górgolas, M. (2008). Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients. Scandinavian Journal of Infectious Diseases, 40(1), 78-80.
Troya J, et al. Long Term Failure of Miltefosine in the Treatment of Refractory Visceral Leishmaniasis in AIDS Patients. Scand J Infect Dis. 2008;40(1):78-80. PubMed PMID: 17852921.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients. AU - Troya,Jesús, AU - Casquero,Angela, AU - Refoyo,Elena, AU - Fernández-Guerrero,Manuel L, AU - Górgolas,Miguel, Y1 - 2007/07/06/ PY - 2007/9/14/pubmed PY - 2008/4/23/medline PY - 2007/9/14/entrez SP - 78 EP - 80 JF - Scandinavian journal of infectious diseases JO - Scand J Infect Dis VL - 40 IS - 1 N2 - We carried out a retrospective and descriptive study of 4 HIV infected patients with relapsing visceral leishmaniasis (VL) seen at 2 tertiary-care hospitals in Spain during the last 6 y, in whom miltefosine was used as a compassionate use treatment at a dosage of 50 mg b.i.d. Patients had a medium CD4 lymphocyte count of 69 cells/microl and were C stage. All patients received at least 2 different anti-leishmanial drugs and had at least 3 relapses before miltefosine treatment (range 3-7). Three patients were treated with miltefosine at a standard dose of 50 mg b.i.d. for 28 d, and the other during 12 months. Despite an initial symptomatic improvement, miltefosine treatment failed to eradicate the infection in all cases. We conclude that the use of miltefosine alone is not strong enough to cure relapsing VL in HIV-1 controlled infected patients. SN - 0036-5548 UR - https://www.unboundmedicine.com/medline/citation/17852921/Long_term_failure_of_miltefosine_in_the_treatment_of_refractory_visceral_leishmaniasis_in_AIDS_patients_ L2 - https://www.tandfonline.com/doi/full/10.1080/00365540701466215 DB - PRIME DP - Unbound Medicine ER -